The PennZone

CHICAGO - PennZone -- R&D Division in Discussions with the European Investment Bank for Financing of up to €25 million.

4,874,126 Series B Warrants Expired Unexercised, Eliminating ~38% of Total Warrant Overhang with Zero Shareholder Dilution.

Entering the $69 Billion Global Animal Health Market Through Veterinary C-Scrub® Wash

Targeting $200.6 Million Revenue and $44.2 Million Adjusted EBITDA by 2029

Record Revenue Growth, Improving Balance Sheet, and Expanding U.S. Operations

AI-Driven Healthcare Innovation, Telehealth Expansion, and High-Margin Proprietary Brands

Cosmos Health Inc. (N A S D A Q: COSM) $COSM continues to execute on a long-term strategy designed to transform the company into a diversified global healthcare platform spanning pharmaceuticals, nutraceuticals, telehealth, medical technologies, proprietary consumer healthcare products, and artificial intelligence-driven drug development.

With operations spanning Europe, North America, and expanding international markets, COSM has built a vertically integrated healthcare ecosystem that combines manufacturing, distribution, research and development, direct-to-consumer products, and digital healthcare services.

Recent company announcements highlight accelerating growth momentum across multiple business segments while management projects substantial revenue, profitability, and balance sheet expansion through 2029.

Entering the Global Animal Health Market

One of the most significant recent developments for Cosmos Health is the company's expansion into the rapidly growing veterinary healthcare sector.

The company recently announced plans to launch a veterinary formulation of its C-Scrub® Wash 4% antimicrobial solution, marking Cosmos Health's first major entry into animal healthcare. Management intends to initially launch the product in the United Kingdom, where the C-Scrub brand already enjoys commercial recognition and established distribution channels, before pursuing broader international expansion opportunities.

The opportunity is substantial. Industry research estimates the global animal health market was valued at approximately $68.7 billion in 2025 and is projected to grow to roughly $156 billion by 2033. This expansion provides Cosmos Health access to a significant new growth market while leveraging existing manufacturing, regulatory, and distribution infrastructure.

European Testing Success Supports Commercial Launch

The planned veterinary expansion follows successful independent testing of C-Scrub Wash 4% under recognized European veterinary standards.

Testing conducted by Quality Assurance & Control Systems Ltd. demonstrated compliance with EN 1656:2019 bactericidal standards and EN 1657:2024 yeasticidal standards. The product successfully met required performance thresholds against Candida albicans at multiple concentrations.

These results establish an important foundation for commercialization efforts and reinforce management's confidence in expanding the C-Scrub platform into new markets and applications.

More on The PennZone

• CAPHRA warns push for ASEAN vape ban ignores science
• Your Mortgage Toolbox Launches Free Mortgage Calculators That Show the Real Monthly Payment and Cash Needed to Close
• ENTOUCH Recognized on Inc.'s 2026 Best Workplaces List for the Third Year Running
• P-Wave Classics Opens Pre-Orders for Volume II of Robert Bage's Hermsprong
• Cabinetworks Group announces recipient of 2025 Plant of the Year

Financial Guidance Highlights Significant Growth Potential

Cosmos Health recently released long-term financial guidance covering the 2026 through 2029 period, outlining what management believes could be a transformational growth phase for the company.

By 2029, management is targeting:

• Revenue of approximately $200.6 million
• Gross profit of approximately $71.2 million
• Adjusted EBITDA of approximately $44.2 million
• Net income of approximately $31.0 million
• Cash balances of approximately $62.9 million
• Stockholders' equity of approximately $92.3 million

These projections represent substantial growth from 2025 results and reflect management's confidence in the scalability of the company's diversified healthcare platform.

Revenue is projected to increase from $65.3 million in 2025 to more than $200 million by 2029, while gross margins are expected to expand significantly as higher-margin proprietary products become a larger percentage of overall sales.

Record First Quarter Results Continue Positive Momentum

The company's first quarter 2026 financial results demonstrated that many of these growth initiatives are already gaining traction.

Cosmos Health reported record first-quarter revenue of $17.9 million, representing a 31% increase compared to the prior-year period. The company also continued strengthening its balance sheet through a significant reduction in liabilities and convertible debt obligations.

Highlights included:

• Record quarterly revenue performance
• Total liabilities reduced by $4.5 million
• Improved balance sheet metrics
• Stockholders' equity increased 7.6%
• Continued momentum entering the second quarter

Management also noted that U.S. expansion initiatives remain actively underway, providing additional opportunities for future growth and market penetration.

Proprietary Brands Drive Margin Expansion

A key component of the Cosmos Health growth strategy centers around expanding its portfolio of proprietary healthcare brands.

The company's growing lineup includes:

Sky Premium Life®

Mediterranation®

bio-bebe®

C-Sept®

C-Scrub®

Management believes these proprietary products offer significantly higher margins than traditional distribution operations and are expected to become increasingly important contributors to future profitability.

As proprietary product sales continue growing, Cosmos Health projects gross margins could expand from approximately 12% to more than 35% by 2029, helping drive substantial improvements in earnings and cash flow generation.

AI-Powered Drug Development and Research Initiatives

Beyond its commercial operations, Cosmos Health continues investing in research and development initiatives enhanced by artificial intelligence technologies.

The company has established partnerships focused on major healthcare challenges including obesity, diabetes, cancer, and other chronic diseases. Through AI-assisted drug repurposing technologies, management seeks to identify new therapeutic opportunities more efficiently while potentially reducing development timelines and associated costs.

More on The PennZone

• Honesdale Painters Launch Season With Act of Community Kindness
• Tuckwell Machinery Launches New Range of Woodworking Machinery
• A Brave Little Hero with Four Paws
• Pittsburgh-Area Author Erica L. Day Releases HER, a Christian Second-Chance Romance and Its Own Comp
• Revenue Optics Expands Its Private Equity Practice as Sponsors Move Inside Sales to the Center of Distribution Value Creation

Current research efforts include novel nutraceutical formulations, proprietary complex generics, specialized root extracts, and innovative over-the-counter healthcare products.

These initiatives provide additional long-term growth opportunities while further diversifying the company's healthcare platform.

Expanding Digital Healthcare Through Telehealth

Cosmos Health has also expanded its reach into digital healthcare through the acquisition of ZipDoctor, Inc., a Texas-based telehealth platform.

The acquisition provides exposure to the growing virtual healthcare market while complementing the company's broader healthcare ecosystem. Management believes telehealth can serve as both a growth driver and a future distribution channel for healthcare products and services.

The combination of telehealth, pharmaceutical manufacturing, distribution, and proprietary healthcare brands creates a diversified operating model that distinguishes Cosmos Health from many traditional healthcare companies of similar size.

Vertically Integrated Platform Creates Strategic Advantages

Through its subsidiary Cana Laboratories, Cosmos Health maintains European GMP-certified manufacturing capabilities supporting pharmaceuticals, nutraceuticals, cosmetics, biocides, and medical devices.

Combined with established distribution operations throughout Greece and the United Kingdom, the company maintains significant control across multiple stages of the healthcare value chain.

This vertically integrated model may provide several competitive advantages, including enhanced operational efficiency, stronger margin control, improved supply chain management, and accelerated commercialization opportunities.

Positioned for Continued Expansion

As healthcare markets continue evolving globally, Cosmos Health appears increasingly positioned to capitalize on opportunities across several high-growth sectors, including animal health, telehealth, nutraceuticals, pharmaceuticals, AI-assisted drug development, and proprietary healthcare products.

With record revenue growth, strengthening financial fundamentals, expanding proprietary product offerings, and a long-term roadmap targeting more than $200 million in annual revenue, Cosmos Health continues to execute on a strategy designed to build a diversified and scalable global healthcare platform.

Investors seeking exposure to a growing healthcare company with multiple potential growth drivers may find Cosmos Health increasingly worthy of attention as management pursues what could be its most significant expansion phase to date.

For more information on $COSM visit:  www.cosmoshealthinc.com, www.skypremiumlife.com,   www.cana.gr/en/home/, www.zipdoctor.co,  https://cloudscreen.gr/en/

Media Contact:
Company Name:  Cosmos Health, Inc. (N A S D A Q: COSM),
Contact: BDG Communications
Email:  cosm@bdgcommunications.com  or info@cosmoshold.com
Phone: (312) 865-0026
Country: United States

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website